The FDA has received six adverse event reports connected to this specific lot of Ozempic (all submitted by Novo Nordisk), but ...

Last October Novo Nordisk announced that it ... An oral version of insulin would be an enormous breakthrough in treating type 1 and type 2 diabetes patients, as freedom from daily injections ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk's decision has been criticized ... make to make sure that we could sustainably supply enough insulin for all people with Type 1 diabetes," Jørgensen told senators.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

Located in Southeastern Brazil, the Montes Claros site is already the largest insulin factory ... Intelligence Centre. Novo Nordisk has not disclosed total sales of type 2 diabetes medication ...